Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib

Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: A head-to-head comparison with alendronate

(2013) Donald S. Williams et al.   BONE

The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits

(2013) Pia Rosgaard Jensen et al.   CALCIFIED TISSUE INTERNATIONAL

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

(2013) Yuriko Furuya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial

(2013) Kim Brixen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation

(2013) Sunao Takeshita et al.   JOURNAL OF CLINICAL INVESTIGATION

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence

(2013) Cristiano A. F. Zerbini et al.   Therapeutic Advances in Musculoskeletal Disease

Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study

(2012) Nadja Fratzl-Zelman et al.   CALCIFIED TISSUE INTERNATIONAL

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

(2012) Bente Langdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Spotlight on Denosumab in Postmenopausal Osteoporosis†

(2011) Marit D. Moen et al.   BIODRUGS

The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking

(2011) P. Leung et al.   BONE

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?

(2011) Douglas C Bauer   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

(2011) Patricia J Masarachia et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

(2011) Tara Cusick et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Suppression of bone formation by osteoclastic expression of semaphorin 4D

(2011) Takako Negishi-Koga et al.   NATURE MEDICINE

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

(2011) C. Jerome et al.   OSTEOPOROSIS INTERNATIONAL

Dissociation of Bone Resorption and Bone Formation in Adult Mice with a Non-Functional V-ATPase in Osteoclasts Leads to Increased Bone Strength

(2011) Kim Henriksen et al.   PLoS One

Heritable sclerosing bone disorders

(2010) Marie-Christine De Vernejoul et al.   Annals of the New York Academy of Sciences

Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

(2010) Dominique D. Pierroz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

(2010) Ian R Reid et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

(2010) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

(2010) Brenda L Pennypacker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Specialized roles for cysteine cathepsins in health and disease

(2010) Jochen Reiser et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys

(2009) G. B. Stroup et al.   CALCIFIED TISSUE INTERNATIONAL

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

BMP-6 and mesenchymal stem cell differentiation

(2009) Slobodan Vukicevic et al.   CYTOKINE & GROWTH FACTOR REVIEWS

TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation

(2009) Yi Tang et al.   NATURE MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osteoclasts secrete non-bone derived signals that induce bone formation

(2008) Morten A. Karsdal et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

(2008) Jacques Yves Gauthier et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

The anabolic action of intermittent PTH in combination with cathepsin K Inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice

(2008) Hirotoshi Yamane et al.   BONE

Bone density, strength, and formation in adult cathepsin K (−/−) mice

(2008) B. Pennypacker et al.   BONE

Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone Remodeling

(2008) Emma C Walker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Association Analysis of WNT10B With Bone Mass and Structure Among Individuals of African Ancestry

(2008) Joseph M Zmuda et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate

(2008) L. Pederson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impaired growth plate function in bmp-6 null mice

(2007) Mark J. Perry et al.   BONE

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

(2007) Karen Fuller et al.   BONE